Home/Filings/4/0001415889-24-027711
4//SEC Filing

Rieger Jayson 4

Accession 0001415889-24-027711

CIK 0001660334other

Filed

Nov 25, 7:00 PM ET

Accepted

Nov 26, 4:15 PM ET

Size

14.4 KB

Accession

0001415889-24-027711

Insider Transaction Report

Form 4
Period: 2024-11-22
Rieger Jayson
DirectorCEO and President
Transactions
  • Purchase

    Series B Warrants (right to buy)

    2024-11-22+140,449140,449 total
    Exercise: $1.33From: 2024-11-22Exp: 2029-11-22Common Stock (140,449 underlying)
  • Gift

    Common Stock

    2024-11-26+50,000882,826 total
  • Purchase

    Common Stock

    2024-11-22+280,898832,826 total
  • Purchase

    Series A Warrants (right to buy)

    2024-11-22+140,449140,449 total
    Exercise: $1.07From: 2024-11-22Exp: 2025-11-22Common Stock (140,449 underlying)
Holdings
  • Common Stock

    (indirect: By Children)
    150
  • Common Stock

    (indirect: By Trust)
    2,301
  • Common Stock

    (indirect: By Trust)
    2,302
  • Common Stock

    (indirect: By Trust)
    2,302
Footnotes (2)
  • [F1]The reported securities are included within 280,898 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.
  • [F2]These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person is a co-trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Issuer

Verrica Pharmaceuticals Inc.

CIK 0001660334

Entity typeother

Related Parties

1
  • filerCIK 0002043558

Filing Metadata

Form type
4
Filed
Nov 25, 7:00 PM ET
Accepted
Nov 26, 4:15 PM ET
Size
14.4 KB